-
1
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-12.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
Sartore-Bianchi, A.4
Arena, S.5
Saletti, P.6
-
2
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
-
3
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
-
4
-
-
79958817037
-
E t al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
-
Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, e t al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-32.
-
(2011)
Cancer
, vol.117
, pp. 4623-4632
-
-
Tran, B.1
Kopetz, S.2
Tie, J.3
Gibbs, P.4
Jiang, Z.Q.5
Lieu, C.H.6
-
5
-
-
79956298812
-
Cetuximab plus irinotecan, fl uorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fl uorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Kohne, C.H.2
Lang, I.3
Folprecht, G.4
Nowacki, M.P.5
Cascinu, S.6
-
6
-
-
67649652208
-
BRAF mutation in metastatic colorectal cancer
-
Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-9.
-
(2009)
N Engl J Med
, vol.361
, pp. 98-99
-
-
Tol, J.1
Nagtegaal, I.D.2
Punt, C.J.3
-
7
-
-
84908219463
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
-
Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 2014; 13: 164-71.
-
(2014)
Clin Colorectal Cancer
, vol.13
, pp. 164-171
-
-
Morris, V.1
Overman, M.J.2
Jiang, Z.Q.3
Garrett, C.4
Agarwal, S.5
Eng, C.6
-
8
-
-
77956513286
-
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma
-
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010; 467: 596-9.
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsai, J.3
Zhang, J.4
Ibrahim, P.N.5
Cho, H.6
-
9
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
-
10
-
-
84879177690
-
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation
-
Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 2013; 23: 1277-83.
-
(2013)
Thyroid
, vol.23
, pp. 1277-1283
-
-
Kim, K.B.1
Cabanillas, M.E.2
Lazar, A.J.3
Williams, M.D.4
Sanders, D.L.5
Ilagan, J.L.6
-
11
-
-
84883875497
-
Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation
-
Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 2013; 31: e351-2.
-
(2013)
J Clin Oncol
, vol.31
, pp. e351-e352
-
-
Munoz, J.1
Schlette, E.2
Kurzrock, R.3
-
12
-
-
84951810474
-
Phase II pilot study of vemurafenib in patients with metastatic BRAFmutated colorectal cancer
-
Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAFmutated colorectal cancer. J Clin Oncol 2015;33:4032-8.
-
(2015)
J Clin Oncol
, vol.33
, pp. 4032-4038
-
-
Kopetz, S.1
Desai, J.2
Chan, E.3
Hecht, J.R.4
O’Dwyer, P.J.5
Maru, D.6
-
13
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
Di Nicolantonio, F.4
Salazar, R.5
Zecchin, D.6
-
14
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
Coffee, E.M.4
Nishino, M.5
Cogdill, A.P.6
-
15
-
-
84927604543
-
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
-
Yaeger R, Cercek A, O'Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21: 1313-20.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1313-1320
-
-
Yaeger, R.1
Cercek, A.2
O'reilly, E.M.3
Reidy, D.L.4
Kemeny, N.5
Wolinsky, T.6
-
16
-
-
84939864059
-
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
-
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373: 726-36.
-
(2015)
N Engl J Med
, vol.373
, pp. 726-736
-
-
Hyman, D.M.1
Puzanov, I.2
Subbiah, V.3
Faris, J.E.4
Chau, I.5
Blay, J.Y.6
-
17
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
-
18
-
-
84863012433
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
-
Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72: 779-89.
-
(2012)
Cancer Res
, vol.72
, pp. 779-789
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
Packman, K.4
Bradley, W.D.5
Lee, R.J.6
-
19
-
-
0034131260
-
Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay
-
Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000; 60: 3147-51.
-
(2000)
Cancer Res
, vol.60
, pp. 3147-3151
-
-
Han, S.Y.1
Kato, H.2
Kato, S.3
Suzuki, T.4
Shibata, H.5
Ishii, S.6
-
20
-
-
44249111440
-
EPIC: Phase III trial of cetuximab plus irinotecan after fl uoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
-
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fl uoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 2311-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2311-2319
-
-
Sobrero, A.F.1
Maurel, J.2
Fehrenbacher, L.3
Scheithauer, W.4
Abubakr, Y.A.5
Lutz, M.P.6
-
21
-
-
44849083804
-
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fl uorouracil
-
Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fl uorouracil. Ann Oncol 2008; 19: 1141-5.
-
(2008)
Ann Oncol
, vol.19
, pp. 1141-1145
-
-
Pfeiffer, P.1
Nielsen, D.2
Bjerregaard, J.3
Qvortrup, C.4
Yilmaz, M.5
Jensen, B.6
-
22
-
-
48349134539
-
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial
-
Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, Bosch A, Cervantes A. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: Results of a phase II single institution trial. Br J Cancer 2008; 99: 455-8.
-
(2008)
Br J Cancer
, vol.99
, pp. 455-458
-
-
Martin-Martorell, P.1
Rosello, S.2
Rodriguez-Braun, E.3
Chirivella, I.4
Bosch, A.5
Cervantes, A.6
-
23
-
-
84873360893
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013; 19: 657-67.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 657-667
-
-
Mao, M.1
Tian, F.2
Mariadason, J.M.3
Tsao, C.C.4
Lemos, R.5
Dayyani, F.6
-
24
-
-
80051625929
-
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
-
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
Davis, M.J.4
Sawyer, A.5
Pochanard, P.6
-
25
-
-
84923341318
-
Increased MAPK reactivation in early resistance to dabrafenib/ trametinib combination therapy of BRAF-mutant metastatic melanoma
-
Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib/ trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 2014; 5: 5694.
-
(2014)
Nat Commun
, vol.5
, pp. 5694
-
-
Long, G.V.1
Fung, C.2
Menzies, A.M.3
Pupo, G.M.4
Carlino, M.S.5
Hyman, J.6
-
26
-
-
0024404145
-
GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours
-
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692-6.
-
(1989)
Nature
, vol.340
, pp. 692-696
-
-
Landis, C.A.1
Masters, S.B.2
Spada, A.3
Pace, A.M.4
Bourne, H.R.5
Vallar, L.6
-
27
-
-
77955655753
-
The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways
-
Wilson CH, McIntyre RE, Arends MJ, Adams DJ. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 2010; 29: 4567-75.
-
(2010)
Oncogene
, vol.29
, pp. 4567-4575
-
-
Wilson, C.H.1
McIntyre, R.E.2
Arends, M.J.3
Adams, D.J.4
-
28
-
-
84933040790
-
Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
-
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358-67.
-
(2015)
Cancer Discov
, vol.5
, pp. 358-367
-
-
Ahronian, L.G.1
Sennott, E.M.2
Van Allen, E.M.3
Wagle, N.4
Kwak, E.L.5
Faris, J.E.6
-
29
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
Cancer Genome Atlas, N.1
-
30
-
-
84941350733
-
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
-
Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015; 162: 1271-85.
-
(2015)
Cell
, vol.162
, pp. 1271-1285
-
-
Hugo, W.1
Shi, H.2
Sun, L.3
Piva, M.4
Song, C.5
Kong, X.6
-
31
-
-
55949099916
-
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
-
Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, Arribas J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 2008; 99: 1607-12.
-
(2008)
Br J Cancer
, vol.99
, pp. 1607-1612
-
-
Vilar, E.1
Scaltriti, M.2
Balmana, J.3
Saura, C.4
Guzman, M.5
Arribas, J.6
-
32
-
-
84949009842
-
Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
-
Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PloS ONE 2015; 10: e0140712.
-
(2015)
Plos ONE
, vol.10
-
-
Lanman, R.B.1
Mortimer, S.A.2
Zill, O.A.3
Sebisanovic, D.4
Lopez, R.5
Blau, S.6
|